Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD34+ selected donor stem cell infusion
- Development stage
- Unknown
- Lead developer
- Cincinnati Children's Hospital Medical Center
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This cellular therapy consists of CD34+ selected hematopoietic stem cells (HSCs) derived from an allogeneic donor. Developed by Cincinnati Children's Hospital Medical Center (CCHMC), it is specifically designed for pediatric patients with primary immunodeficiency diseases (PID) or bone marrow failure (BMF) syndromes who exhibit waning donor chimerism or graft dysfunction following a previous allogeneic stem cell transplant. The therapy involves the isolation of CD34+ cells from the original donor's mobilized peripheral blood using the CliniMACS system (Miltenyi Biotec) to achieve T-cell depletion, which minimizes the risk of graft-versus-host disease (GVHD). Unlike standard hematopoietic stem cell transplants, this infusion is administered without a preparative conditioning regimen. The primary therapeutic goal is to augment graft function, enhance donor chimerism, and improve immune reconstitution and hematologic parameters such as white blood cell and platelet counts.
- Other names
- Post Transplant CD34+ Selected Stem Cell InfusionCD34+ selected hematopoietic stem cells
Beyond the preview
Go deeper on CD34+ selected donor stem cell infusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD34+ selected donor stem cell infusion.